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Genome-wide association analysis 
of type 2 diabetes in the EPIC-
InterAct study
Lina Cai et al.#
Type 2 diabetes (T2D) is a global public health challenge. Whilst the advent of genome-
wide association studies has identified >400 genetic variants associated with T2D, our 
understanding of its biological mechanisms and translational insights is still limited. The 
EPIC-InterAct project, centred in 8 countries in the European Prospective Investigations 
into Cancer and Nutrition study, is one of the largest prospective studies of T2D. Established 
as a nested case-cohort study to investigate the interplay between genetic and lifestyle 
behavioural factors on the risk of T2D, a total of 12,403 individuals were identified as incident 
T2D cases, and a representative sub-cohort of 16,154 individuals was selected from a larger 
cohort of 340,234 participants with a follow-up time of 3.99 million person-years. We describe 
the results from a genome-wide association analysis between more than 8.9 million SNPs and 
T2D risk among 22,326 individuals (9,978 cases and 12,348 non-cases) from the EPIC-InterAct 
study. The summary statistics to be shared provide a valuable resource to facilitate further 
investigations into the genetics of T2D.
Background & Summary
Diabetes is one of the fastest-growing health challenges of the 21st century. The most common form of diabetes, 
type 2 diabetes (T2D), is a complex multifactorial disease which can lead to further severe health consequences 
such as cardiovascular diseases and premature death. In 2019, 463 million people worldwide were living with 
diabetes according to the International Diabetes Federation, and this number is expected to rise to 700 million 
by 20451. Genome-wide association studies (GWAS) have made considerable progress in identifying genetic risk 
factors and in providing evidence for more in-depth understanding of the biological and pathological pathways 
underlying T2D. A recent study performed a meta-analysis of T2D across 32 GWAS of European ancestry par-
ticipants and identified 243 genome-wide significant loci (403 distinct genetic variants) associated with T2D 
risk2. The summary statistics from this meta-analysis are publicly available; however, the GWAS results for each 
participating study, including EPIC-InterAct, cannot be acquired easily.
To date, a growing body of comprehensive methods has been developed for downstream analyses of GWAS. 
Sharing of summary statistics can help enable these analyses, for example, by providing researchers with a more 
convenient way to look-up genetic association effect estimates to conduct causal inference analyses using meth-
ods such as two-sample Mendelian Randomization which assumes samples are non-overlapping3,4. In addition, 
sharing GWAS results can help researchers to further their understanding of the shared genetic basis of T2D 
with other traits of interest, to perform fine-mapping to pinpoint the causal genetic variants or identify genetic 
loci shared with other risk factors and disease outcomes. Therefore, the aim of this current work was to provide a 
reference dataset for researchers to utilize in order to conduct further genetic analyses, generate hypotheses and 
improve understanding of the aetiology, the biological pathways and mechanisms of T2D and related metabolic 
and cardiovascular diseases.
#A full list of authors and their affiliations appears at the end of the paper. 
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Methods
Study design and participants. The EPIC-InterAct study is a large-scale prospective study nested in the 
European Prospective Investigation into Cancer (EPIC) study, facilitating the investigation of genetic and lifestyle 
factors on the risk of T2D among European populations. A total of 26 research centres located in eight different 
European countries (France, Italy, Spain, UK, the Netherlands, Germany, Sweden, and Denmark) were included. 
The study design, sample collection and genotyping have been described in detail previously5,6.
In brief, the EPIC-InterAct study adopted a nested case-cohort design. A total of 340,234 participants with 
stored blood and information reported on diabetes status from the wider EPIC study were followed up for 3.99 
million person-years. During the follow-up, researchers from participating study centres ascertained and verified 
12,403 incident cases of T2D through self-reported history of T2D, doctor diagnosed T2D and diabetes medica-
tion use, linkage to primary care registers, secondary care registers, medication use (pharmacy/ drug registers), 
hospital admissions and mortality data or local and national diabetes and pharmaceutical registers5. To select a 
representative sub-cohort, a total of 16,835 participants were randomly selected at baseline with numbers propor-
tional to the number of participants in each participating centre. Participants with prevalent (n = 548), unknown 
(n = 129) and post-censoring diabetes status (n = 4) were excluded, with a total of 16,154 diabetes-free individu-
als remaining in the EPIC-InterAct sub-cohort (Fig. 1).
DNA samples and genotyping platforms. Blood samples were collected at recruitment and stored in 
liquid nitrogen at the International Agency for Research into Cancer (IARC) in Lyon, France, or in local biore-
positories except for Umeå where −80 °C freezers were used. DNA was extracted and quantified, with details of 
sample handling described elsewhere5,7.
Available EPIC-InterAct DNA samples were genotyped using two genotyping platforms. A total of 10,023 
EPIC-InterAct participants were randomly selected for genome-wide genotyping using the Illumina 660W-Quad 
BeadChip (Illumina, Inc., San Diego, California) at the Wellcome Trust Sanger Institute with the number of indi-
viduals selected per centre being proportional to the percentage of total cases in that centre, except the Danish 
participants who did not have available DNA samples at the time7. Samples were excluded if they had a low call 
rate (<95.4%), a lack of concordance with previous genotyping results, a mismatch between self-reported sex and 
the sex inferred from genetic data (X chromosome heterozygosity) or missing data, or they were autosomal hete-
rozygosity outliers, overall array intensity outliers, ethnic outliers (non-European ancestry) or duplicate samples. 
Related individuals in the Illumina 660 W genotyping array group were identified based on an identity by descent 
(IBD) pi-hat threshold of 0.1875 (mid-point between second-degree (0.25) and third-degree (0.125) relatives), 
and those with the largest number of relatives or the lowest call rate were removed preferentially. A total of 9,290 
samples genotyped on the Illumina 600 W array passed initial sample quality control (QC).
A total 13,474 individuals from the remaining of EPIC-InterAct samples (including the Danish samples) 
were genotyped using the Illumina core-exome 12v1 and 24v1 arrays at Cambridge Genomic Services in the 
Department of Pathology at the University of Cambridge. The two core-exome arrays are very similar; hence the 
genotype data were merged for further analyses. Following comparable QC procedures as above, a total of 13,202 
samples genotyped using the core-exome arrays passed initial sample QC.
Following initial sample QC, an additional 166 participants who had relatives (IBD pi-hat threshold of 0.1875) 
across the different genotyping arrays (Illumina 660 W vs Illumina core-exome) were excluded, and a total of 
22,326 individuals were included in the downstream genetic analyses (Fig. 1; Table 1).
Genotype imputation. Prior to imputation, single nucleotide polymorphisms (SNPs) were removed if they 
had Hardy Weinberg p-value < 10−6 or were not found in the Haplotype Reference Consortium (HRC) reference 
panel version 1.08, were A/T or G/C with minor allele frequency (MAF) >0.4, had an allele frequency difference 
>0.2 with the reference panel, or were short insertion-deletion mutations (indels). A total of 553,115 and 366,044 
SNPs passed pre-imputation SNP QC in the Illumina 660W-Quad BeadChip and combined Illumina core-exome 
arrays, respectively. Imputation was performed using the HRC reference panel and IMPUTE v2.3.2 software9. 
Monomorphic and singleton SNPs and those with imputation quality (info) <0.3 were excluded prior to genetic 
analyses.
Fig. 1 Overview of the EPIC-InterAct study, genotyping and genome-wide association meta-analysis for T2D 
in 22,326 participants.
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Genome-wide association meta-analysis. For genome-wide association analysis of T2D, all 22,326 
included individuals in the EPIC-InterAct study were of European ancestry, including 9,978 type 2 diabetes cases 
(including 616 cases from the sub-cohort) and 12,348 non-cases from the sub-cohort, among whom 9,178 partic-
ipants were genotyped on the Illumina 660 W array and 13,148 using the core-exome array (Fig. 1; Table 1). The 
mean follow-up time for the EPIC-InterAct cases included in the analyses was 6.8 years (standard deviation (s.d.) 
=3.3 years), and 12.2 years (s.d. =2.0 years) for the sub-cohort.
We used logistic regression to test genome-wide associations with T2D, rather than Prentice- weighted Cox 
regression that takes into account the case-cohort design of EPIC-InterAct. Logistic regression was chosen both 
for computational efficiency and because it has been shown to have greater power than Prentice-weighted Cox 
regression to detect SNP-disease associations10. All T2D incident cases including those from the sub-cohort 
were coded as ‘1’, and non-cases from the sub-cohort were coded as ‘0’. To estimate the association between 
T2D and each genetic variant, we performed logistic regression under an additive genetic model, adjusting for 
age, sex, study centre and the first four genetic principal components to account for population structure using 
QUICKTEST Version 0.9811. Dummy variables for each study centre (combining the six centres in France due to 
the small sample size in each French centre) were included in the model to account for the differences between 
participants from each country and the potential confounding by larger scale relatedness between participants 
from each study centre. Genome-wide analyses were performed separately for each genotyping array and com-
bined using an inverse variance weighted fixed-effect meta-analysis in METAL12. The final meta-analysis had an 
effective sample size12 of up to 21,924.
Ethics statement. The EPIC-InterAct study was approved by the local ethics committee in the participating 
countries and the Internal Review Board of the International Agency for Research on Cancer. All participants 
gave written informed consent. The study was coordinated by the Medical Research Council Epidemiology Unit 
at the University of Cambridge.
Data records
Genome-wide association summary statistics from the meta-analysis of T2D in the EPIC-InterAct study and 
Cox-regression analysis results for the 370 top T2D SNPs from the recently published DIAMANTE study2 are 
available to download from the Dryad Digital Repository (https://doi.org/10.5061/dryad.qnk98sfcg)13.
The genome-wide summary statistics are in tab-delimited TXT format, including rsID (based on the HRC 
reference panel), chromosome, position (using the reference genome GRCh37 (hg19)), effect allele, other allele, 
frequency of effect allele, effect estimate, standard error of the effect estimate, p-value, assessment of heterogene-
ity across the two genotyping arrays, total sample size and effective sample size for the SNP.
The Cox-regression analysis results are in tab-delimited TXT format, including MarkerName (hg19), rsID 
(based on the HRC reference panel), chromosome, position (using the reference genome GRCh37 (hg19)), effect 
allele, other allele, frequency of effect allele, beta, standard error of beta, hazard ratio (HR), lower-bound of 95% 
confidence interval (CI) of HR, upper-bound of 95% confidence interval (CI) of HR, p-value, imputation quality, 
total sample size.
Alternatively, the genome-wide summary statistics data is also available in NHGRI-EBI’s GWAS Catalog with 
accession ID GCST9000693414. It can be downloaded via the following ftp link: ftp://ftp.ebi.ac.uk/pub/databases/
gwas/summary_statistics/GCST90006934.
In addition, access to individual-level EPIC data is available through the International Agency for Research on 
Cancer (IARC): https://epic.iarc.fr/access/, where there is a controlled-access repository. A clear and open access 
request mechanism and data use agreement is in place.
Technical Validation
For the meta-analysis, only SNPs with minor allele frequency (MAF) > 0.5%, imputation information score > 0.4, 
Hardy-Weinberg Equilibrium p-value > 1 × 10−6 and association effect standard error < 10 from each genotyping 
platform were included. After the meta-analysis, 31 SNPs with heterogeneity p-value < 1 × 10−5 were excluded. 
A total of 8,924,492 SNPs remained in the shared meta-analysis results. The numbers of genetic variants in each 
MAF bin are shown in Table 2.
Diabetes 
Outcome
Genotyping Array
TotalIll660W Core-exome
non-case 4,625 7,723 12,348
case 4,553 5,425 9,978
Total 9,178 13,148 22,326
Table 1. Sample size of the EPIC-InterAct T2D GWAS analysis by diabetes outcome status and genotyping array.
MAF bin (0.005,0.01] (0.01, 0.05] (0.05, 0.1] (0.1,0.2] (0.2, 0.3] (0.3,0.4] (0.4,0.5]
N of SNPa 1,201,837 2,287,670 1,117,493 1,429,429 1,074,208 937,594 876,261
Table 2. Number of SNPs in each minor allele frequency (MAF) bin in the final EPIC-InterAct T2D GWAS 
meta-analysis result after quality control. aSNPs with meta-analysis heterogeneity p value < 10−5, imputation 
info <0.4 and minor allele count <  = 10 were excluded.
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The Manhattan plot is shown in Fig. 2. The quantile-quantile plot (Fig. 3) showed no evidence of inflation 
from confounding or other biases, supported by the LD score regression15 intercept, which was very close to 
1 (1.0054); therefore, no genomic control correction was performed. As a positive control, the top independ-
ent genome-wide significant signal from the meta-analysis was the well-established TCF7L2 variant rs790314616 
(p = 1.30 × 10−38).
Fig. 2 Manhattan plot of genome-wide association meta-analysis for T2D in 22,326 participants from the 
EPIC-InterAct study. The x-axis is chromosome position (Build 37), and the y-axis is the negative log10 p-value 
(−log10(p)) of the association between each genetic variant and T2D. Points represent a genetic variant included 
in the study (only SNPs with a p-value < 0.1 are illustrated in the plot). The red horizontal line represents the 
genome-wide significance threshold p-value of 5 × 10−8.
Fig. 3 Quantile-Quantile plot of the T2D genome-wide association meta-analysis results in the EPIC-InterAct 
study.
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Fig. 4 Log(hazard ratios) from the Prentice-weighted Cox regression model and log(odds ratios) from the 
logistic model for established genetic variants from a previous meta-analysis2 with p < 0.05 in the EPIC-
InterAct T2D GWAS summary statistics (n = 175).
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Because logistic regression may potentially yield inflated effect estimates when applied in a case-cohort 
study10, we compared the strength of associations from the GWAS meta-analysis (logistic regression) and 
Prentice-weighted Cox-regression analyses adjusting for sex, study centre and first four principal components 
with age as the underlying time-scale variable for established T2D genetic variants. A total of 370 SNPs from the 
recently published DIAMANTE study2 are available in our HRC imputed EPIC-InterAct genotype data. Among 
these, 175 SNPs with p-value < 0.05 in the EPIC-InterAct meta-analysis results were included in the comparison. 
The Pearson correlation coefficient between the log of hazard ratios from the Cox-regression model and the log 
of odds ratios from logistic regression models was 0.98 (p = 3.1 × 10−126) (Fig. 4), showing the effects are highly 
comparable.
Code availability
IMPUTE v2.3.2: https://mathgen.stats.ox.ac.uk/impute/impute_v2.html QUICKTEST Version 0.98: http://toby.
freeshell.org/software/quicktest.shtml METAL: https://genome.sph.umich.edu/wiki/METAL All other analyses, 
including the Prentice-weighted Cox-regression analyses, were performed using R 3.4.217.
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